IndiaMart
FIEO
Survodutide 10mg is a dual agonist peptide that targets both GLP-1 (Glucagon-Like Peptide-1) and glucagon receptors, designed to support advanced metabolic and obesity-related research. Known for its dual action in reducing appetite and enhancing energy expenditure, Survodutide is at the forefront of modern metabolic regulation and anti-obesity studies.
Developed to explore mechanisms of fat oxidation, glucose metabolism, and energy homeostasis, Survodutide 10mg offers researchers a powerful tool for investigating insulin sensitivity, lipid metabolism, and satiety signaling pathways.
BLUEPILL EXPRESS, a global merchant exporter, provides Survodutide 10mg manufactured in GMP-certified facilities in India and China, ensuring pharmaceutical-grade purity, stability, and authenticity. Each batch undergoes stringent HPLC and Mass Spectrometry (MS) testing for purity and bioactivity confirmation, meeting international research and export standards.
Key Features of Survodutide 10mg:
- Dual GLP-1 and glucagon receptor agonist for metabolic research
- Supports studies in obesity, diabetes, and energy metabolism
- Promotes fat oxidation, appetite regulation, and improved glucose tolerance
- High-purity peptide verified through HPLC and MS analysis
- Manufactured in GMP-certified units in India and China
- Distributed globally by BLUEPILL EXPRESS – Merchant Exporter of Peptides and APIs
- COA, MSDS, and export documentation available for all shipments
- Suitable for research institutions, biotech laboratories, and clinical development
- Available in bulk, OEM, or custom packaging as per client requirement
BLUEPILL EXPRESS is a leading merchant exporter of research peptides, active pharmaceutical ingredients (APIs), and custom formulations, with trusted manufacturing networks in India and China. The company specializes in GMP-compliant production and global export of premium-grade biochemicals for research and pharmaceutical innovation.
Alongside Survodutide 10mg, BLUEPILL EXPRESS offers a full portfolio of GLP-1 analogs and metabolic peptides, including Semaglutide, Retatrutide, Cagrilintide, and Mazdutide, empowering researchers in the fields of obesity, diabetes, and endocrinology.
